Lung erosion following adjuvant immunotherapy with pembrolizumab: a case report

BACKGROUND: Pembrolizumab as immunotherapy is increasingly used in adjuvant, neoadjuvant, and standalone therapy and has been described as safe. We share an experience of lung erosion post-thoracic surgery with the use of adjuvant pembrolizumab. CASE PRESENTATION: A 65-year-old Chinese gentleman wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Leow, Lowell, Anbudurai, Manisha, Yue, Li, Tam, John Kit Chung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559492/
https://www.ncbi.nlm.nih.gov/pubmed/37803471
http://dx.doi.org/10.1186/s13256-023-04162-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559492/
https://www.ncbi.nlm.nih.gov/pubmed/37803471
http://dx.doi.org/10.1186/s13256-023-04162-y

Ejemplares similares